Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study.
Nakatomi, Yasuhito, Mizuno, Kei, Ishii, Akira et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014 · DOI
Quick Summary
This study used a special brain imaging technique called PET scans to look for signs of inflammation in the brains of ME/CFS patients. Researchers found that people with ME/CFS had higher levels of brain inflammation markers in several key brain regions compared to healthy controls. The amount of inflammation was linked to how severe patients' cognitive problems, pain, and depression were.
Why It Matters
This was the first direct neuroimaging evidence of brain inflammation in ME/CFS patients, moving beyond speculation to demonstrate a biological mechanism. The correlation between inflammation levels and symptom severity suggests neuroinflammation may be central to ME/CFS pathophysiology, potentially supporting development of both objective diagnostic biomarkers and targeted anti-inflammatory treatments.
Observed Findings
Brain inflammation markers (translocator protein binding) were 45-199% higher in multiple brain regions of CFS/ME patients compared to healthy controls.
Inflammation in the amygdala, thalamus, and midbrain correlated with severity of cognitive impairment.
Inflammation in the cingulate cortex and thalamus correlated with pain severity.
Inflammation in the hippocampus correlated with depression severity.
Inferred Conclusions
Neuroinflammation is widespread across multiple brain regions in ME/CFS patients and represents a key feature of the disease.
The strength of regional inflammation correlates with the severity of specific neuropsychological symptoms, suggesting inflammation contributes to symptom manifestation.
Neuroinflammation assessment may be essential for objective diagnosis and for understanding ME/CFS pathophysiology.
Remaining Questions
Does neuroinflammation precede ME/CFS symptom onset, or does it develop as a consequence of the disease?
Do anti-inflammatory treatments reduce both the neuroinflammation and the associated symptoms in ME/CFS patients?
How does this neuroinflammation evolve over time, and do inflammation levels correlate with disease course and recovery?
What This Study Does Not Prove
This study does not prove that neuroinflammation causes ME/CFS symptoms—only that the two are correlated. The small sample size and lack of longitudinal follow-up mean findings cannot confirm whether inflammation precedes symptom onset or changes with disease progression. It also does not establish whether targeting this inflammation would effectively treat the disease.